Zenas BioPharma Files 2024 10-K, Reports $81M R&D Spend
Ticker: ZBIO · Form: 10-K · Filed: Mar 11, 2025 · CIK: 1953926
Sentiment: neutral
Topics: 10-K, pharmaceuticals, R&D, financials
TL;DR
Zenas BioPharma 2024 10-K is in: $81.2M R&D, $175.9M assets. Watch Xencor & BMS deals.
AI Summary
Zenas BioPharma, Inc. filed its 2024 10-K on March 11, 2025, reporting its financial performance for the fiscal year ending December 31, 2024. The company, incorporated in Delaware, operates in the pharmaceutical preparations sector. Key financial figures include Research and Development expenses of $81.24 million and total assets of $175.89 million. The filing also details various agreements and preferred stock series, including Series A, B, and C, with associated dates and related parties like Xencor, Inc. and BMS.
Why It Matters
This filing provides a comprehensive overview of Zenas BioPharma's financial health and operational activities for 2024, crucial for investors assessing the company's progress and future prospects in the pharmaceutical industry.
Risk Assessment
Risk Level: medium — The company operates in the highly regulated and competitive pharmaceutical industry, with significant R&D expenses and reliance on strategic partnerships.
Key Numbers
- $81.24M — Research and Development Expense (Significant investment in innovation for the fiscal year 2024.)
- $175.89M — Total Assets (Represents the company's total resources as of December 31, 2024.)
- $1.76M — Fair Value Adjustment of Convertible Notes (Indicates changes in the valuation of convertible debt instruments.)
Key Players & Entities
- Zenas BioPharma, Inc. (company) — Filer of the 10-K
- 2024-12-31 (date) — Fiscal year end
- 2025-03-11 (date) — Filing date
- $81.24 million (dollar_amount) — Research and Development Expense
- $175.89 million (dollar_amount) — Total Assets
- Xencor, Inc. (company) — Related party in agreements
- BMS (company) — Related party in convertible notes
- Series A Preferred Stock (security) — Mentioned in agreements
- Series B Preferred Stock (security) — Mentioned in agreements
- Series C Preferred Stock (security) — Mentioned in agreements
FAQ
What were Zenas BioPharma's total revenues for the fiscal year ending December 31, 2024?
The provided excerpt does not explicitly state the total revenues for the fiscal year ending December 31, 2024. It focuses on expenses and assets.
What is the nature of the agreements between Zenas BioPharma and Xencor, Inc. mentioned in the filing?
The filing mentions agreements related to Series A and Series B Preferred Stock involving Zenas BioPharma and Xencor, Inc., with specific dates in 2020, 2021, and 2023.
What was the total amount of Zenas BioPharma's net loss for the fiscal year ending December 31, 2024?
The excerpt does not provide information on the company's net loss for the fiscal year ending December 31, 2024.
What are the details of the convertible promissory notes with BMS?
The filing references 'BmsConvertiblePromissoryNotesMember' in relation to Series C Preferred Stock, with a specific date of May 3, 2024, indicating a financial transaction or agreement.
What is the company's primary business activity?
Zenas BioPharma, Inc. operates in the Pharmaceutical Preparations sector, as indicated by its Standard Industrial Classification code [2834].
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 11, 2025 regarding Zenas BioPharma, Inc. (ZBIO).